Background and Aims: The pivotal trial of the MiniMed™ 780G system showed that optimized settings of active insulin time (2 hours) and target glucose (100mg/dL) improved glycemic outcomes.1 This study analyzed real-world glycemic outcomes of individuals with T1D in Chile, 6 months after AHCL initiation with different settings.

Methods: Data from 37 MiniMed™ 780G system users (aged 5-76 years, mean±SD of 29.3±19.3 years) at 12 centers throughout Chile were prospectively collected and analyzed. Effects of active insulin time (AIT) and glucose target on mean GMI, TIR (70-180mg/dL) , time at <70mg/dL (TBR) and time at >180mg/dL (TAR) were determined using 14 days of sensor glucose data pre-AHCL and at 180 days post-AHCL initiation.

Results: Overall TIR increased from 74.1% to 78.4% (p<0.01) , and mean TBR and GMI were 2.7% and 6.7% at study end, respectively. Individuals (N=23) with optimized settings achieved the highest TIR (80.1%) and lowest TBR (2.6%) (Figure 1) .

Conclusion: In this real-world data analysis, MiniMed™ 780G system users who optimized their active insulin time and target glucose settings achieved the highest TIR and lowest TBR.


M.Castro: Employee; Medtronic. C.Carrasco bonilla: Employee; Medtronic. J.C.Leon macedo: Employee; Medtronic. M.Gutierrez: Employee; Medtronic. Z.C.Valera lopez: Employee; Medtronic. A.Daghero: Employee; Medtronic.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at